845543-86-4

Basic information

• Product Name: (2S,3S)-2-(3,5-difluorobenzyl)-3-((R)-2-(tert-butoxycarbonyl)-1,2,3,4-tetrahydroisoquinolin-3-yl)-3-hydroxypropanoic acid
• Synonyms: (2S,3S)-2-(3,5-difluorobenzyl)-3-((R)-2-(tert-butoxycarbonyl)-1,2,3,4-tetrahydroisoquinolin-3-yl)-3-hydroxypropanoic acid
• CAS NO: 845543-86-4
• Molecular Weight: 447.479
• Mol File: 845543-86-4.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: (2S,3S)-2-(3,5-difluorobenzyl)-3-((R)-2-(tert-butoxycarbonyl)-1,2,3,4-tetrahydroisoquinolin-3-yl)-3-hydroxypropanoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: (2S,3S)-2-(3,5-difluorobenzyl)-3-((R)-2-(tert-butoxycarbonyl)-1,2,3,4-tetrahydroisoquinolin-3-yl)-3-hydroxypropanoic acid(845543-86-4)
• EPA Substance Registry System: (2S,3S)-2-(3,5-difluorobenzyl)-3-((R)-2-(tert-butoxycarbonyl)-1,2,3,4-tetrahydroisoquinolin-3-yl)-3-hydroxypropanoic acid(845543-86-4)

Safety Data

• Hazardous Substances Data: 845543-86-4(Hazardous Substances Data)

Upstream product

• 845543-81-9 tert-butyl (3R)-3-(hydroxymethyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate 
• 312639-49-9 N-Boc-(D)-Tic methyl ester 
• 78879-20-6 D-N-tert-butoxycarbonyl-1,2,3,4-tetrahydroisoquinolinoline-3-carboxylic acid 
• 444583-19-1 tert-butyl (3R)-3-formyl-3,4-dihydroisoquinoline-2(1H)-carboxylate 
• 877078-49-4 (S)-4-benzyl-3-(3-(3,5-difluorophenyl)propanoyl)oxazolidin-2-one 
• 1034606-46-6 (R)-tert-butyl 3-((1S,2S)-2-(3,5-difluorobenzyl)-3-((S)-4-benzyl-2-oxooxazolidin-3-yl)-1-hydroxy-3-oxopropyl)-3,4-dihydro-isoquinoline-2(1H)-carboxylate 
• 845543-84-2 C₃₀H₃₆F₂N₂O₆ 

Downstream Products

• 845543-89-7 (R)-tert-butyl3-((4S,5S)-4-(3,5-difluorobenzyl)-2-oxooxazolidin-5-yl)-3,4-dihydroisoquinoline-2(1H)-carboxylate 
• 845543-91-1 C₂₃H₂₈F₂N₂O₃ 
• 845972-71-6 C₃₈H₄₇F₂N₃O₅ 
• 1034607-32-3 C₃₇H₄₅F₂N₃O₄ 
• 1034607-30-1 C₄₄H₅₁F₂N₃O₄ 
• 1034607-41-4 C₄₀H₄₃F₂N₅O₄ 
• 1345968-31-1 C₄₆H₅₄F₂N₄O₅ 
• 1034606-52-4 (4S,5S)-4-(3,5-difluorobenzyl)-5-((R)-2-(4-methoxybenzyl)-1,2,3,4-tetrahydroisoquinolin-3-yl)oxazolidin-2-one 
• 1034606-33-1 (S)-2-((S)-3-butyl-2-oxopyrrolidin-1-yl)-N-((1R,2S)-3-(3,5-difluorophenyl)-1-hydroxy-1-((R)-1,2,3,4-tetrahydroisoquinolin-3-yl)propan-2-yl)propanamide 
• 1034606-31-9 C₃₆H₄₃F₂N₃O₃ 
• 1034606-39-7 C₃₂H₃₅F₂N₅O₃ 
• 1345968-38-8 C₃₂H₃₇F₂N₃O₃ 
• 1034606-35-3 (S)-2-((R)-3-acetamido-3-isobutyl-2-oxopyrrolidin-1-yl)-N-((1R,2S)-3-(3,5-difluorophenyl)-1-hydroxy-1-((R)-1,2,3,4-tetrahydroisoquinolin-3-yl)propan-2-yl)-4-phenylbutanamide 
• 1034606-41-1 (1S,2S)-1-((R)-2-(4-methoxybenzyl)-1,2,3,4-tetrahydroisoquinolin-3-yl)-2-amino-3-(3,5-difluorophenyl)propan-1-ol 

Relevant articles and documents

Synthesis and in vivo evaluation of cyclic diaminopropane BACE-1 inhibitors

The synthesis, evaluation, and structure-activity relationships of a set of related constrained diaminopropane inhibitors of BACE-1 are described. The full in vivo profile of an optimized inhibitor in both normal and P-gp deficient mice is compared with data generated in normal rats.

CYCLIC AMINE BACE-1 INHIBITORS HAVING A BENZAMIDE SUBSTITUENT

Disclosed are compounds of the formula or a pharmaceutically acceptable salt or solvate thereof, wherein R is-C(O)-N(R27)(R28) or and the remaining variables are as defined in the specification. Also disclosed are pharmaceutical compositions comprising the compounds of formula I. Also disclosed are methods of treating cognitive or neurodegenerative diseases such as Alzheimer’s disease. Also disclosed are pharmaceutical compositions and methods of treating cognitive or neurodegenerative diseases comprising the compounds of formula I in combination with a β-secretase inhibitor other than those of formula I, an HMG-CoA reductase inhibitor, a gamma-secretase inhibitor, a non-steroidal anti-inflammatory agent, and N-methyl-D-aspartate receptor antagonist, a cholinesterase inhibitor or an anti-amyloid antibody.